BeiGene Ltd (06160), a leading Chinese oncology treatments developer, witnessed a surge of 5.97% in its stock price during Friday's trading session, significantly outperforming the broader market.

The rally was fueled by the company's announcement that several of its oncology products will be included in China's National Medical Insurance Drug Catalog, effective from January 1, 2025. This inclusion is expected to significantly boost the marketing and sales of these products, as they will now be covered by the national medical insurance program, making them more accessible to patients across the country.

BeiGene's inclusion in the national drug catalog underscores the company's commitment to developing innovative oncology treatments and its strong positioning within the rapidly growing Chinese healthcare market. As the company continues to expand its product portfolio and solidify its market presence, further positive developments are anticipated, potentially driving sustained investor interest and stock price growth.